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https://doi.org/10.1016/j.jaip.2018.05.032OBJECTIVE: To evaluate the prevalence and characteristics of
patients eligible to anti-IL-5 treatment and severe asthma in an
unselected cohort of adult-onset asthma.
METHODS: Seinäjoki Adult Asthma Study is a 12-year follow-up
study of patients with new-onset adult asthma (n [ 203). Prev-
alence was estimated based on information collected at 12-year
follow-up visit. Health care use was collected from the whole
12-year follow-up period.
RESULTS: The prevalence of anti-IL-5-treatable patients was
2%, when the following criteria were used: daily use of medium-
to-high inhaled corticosteroid (ICS) dose and long-acting b2-
agonist, ‡2 exacerbations/previous year and blood eosinophil
count ‡300 cells/mL or fraction of exhaled nitric oxide ‡ 50
ppb. The prevalence of severe asthma, as deﬁned according to
European Respiratory Society/American Thoracic Society, was
5.9%, and only 1 patient met criteria for both groups. When
compared with anti-IL-5 eligible patients, severe asthmatics
were more often current smokers at diagnosis, obese, used
higher ICS dose, and had higher blood neutrophils 12 years
after diagnosis. Both groups differed from nonsevere asthma by
a higher number of all and unplanned respiratory-related visits
to health care. Severe asthmatics showed the highest number of
hospitalizations.
CONCLUSIONS: In a cohort of unselected consecutive patients
with adult-onset asthma, 5.9% fulﬁlled criteria for severe asthma
and 2% qualiﬁed for anti-IL-5 treatment. Both groups represent
a high burden to health care and speciﬁcally targeted treatment
could lead to lower use of health care at long term.  2019 The
Authors. Published by Elsevier Inc. on behalf of the American
Academy of Allergy, Asthma & Immunology. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (J Allergy Clin
Immunol Pract 2019;7:165-74)
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ACT- Asthma Control Test
ATS- American Thoracic Society
CI- Conﬁdence intervalERS- European Respiratory Society
FeNO- Fraction of exhaled nitric oxide
FEV1- Forced expiratory volume in 1 second
GINA- Global Initiative for Asthma
ICS- Inhaled corticosteroidLABA- Long-acting b2-agonist
OCS- Oral corticosteroid
SA- Severe asthmaSAAS- Seinäjoki Adult Asthma StudyRecently, asthma has been considered to manifest in different
phenotypes requiring different treatment approaches. Age at
onset is a critical factor separating different phenotypes. Asthma
starting in childhood often coexists with atopy/allergy, is domi-
nated by Th2 inﬂammation, and responds well to therapy with
inhaled corticosteroids (ICS). However, asthma starting at
adulthood is more often nonatopic, less responsive to ICS
treatment, and has less favorable prognosis. Adult-onset
asthma has been proposed to consist of subphenotypes such as
obesity-related, smoking, severe obstructive, mild-to-moderate/
well-controlled, and atopic asthma.1-3 Late-onset eosinophilic
(often severe) asthma has been considered to be one of the
adult-onset asthma phenotypes.1,3
Late-onset eosinophilic asthma is characterized by persistent
eosinophilic airway inﬂammation despite the use of corticoste-
roid therapy. It is associated with a lower rate of allergy;
frequently there is no obvious family history of asthma and it is
often severe from onset.3 Many of these patients suffer from
frequent exacerbations and may respond poorly to inhaled ste-
roid therapy. This condition is associated with substantial health
care costs due to unplanned health care visits, emergency
department visits, and hospital admissions. Previous studies have
emphasized the importance of eosinophils in mediating exacer-
bations,4 and therefore the resolution of eosinophilic inﬂam-
mation has been suggested as a promising therapeutic strategy to
reduce exacerbations. IL-5 is a critical cytokine for eosinophil
maturation, survival, and activation.5,6 Neutralization of its ef-
fects by anti-IL-5 antibodies such as mepolizumab or reslizumab
leads to the reduced number of eosinophils. Benralizumab is an
anti-IL5 receptor antibody that depletes eosinophils through
antibody-dependent cell-medicated cytotoxicity. In clinical trials
in patients with severe glucocorticoid-resistant eosinophilic
asthma, these antibodies decreased exacerbation rate, had a
glucocorticoid-sparing effect, and improved asthma-related
quality of life and lung function.7-11
Typically, inclusion criteria for anti-IL-5 studies have been the
use of moderate-to-high ICS dose together with long-acting b2-
agonist (LABA) or another controller and at least 2 exacerbations
requiring oral corticosteroid (OCS) during the previous year.7-11
For blood eosinophil levels, 150, 300, or 400 cells/mL have
been used as a criterion for inclusion or alternatively, fraction of
exhaled nitric oxide (FeNO) 50 ppb, or sputum eosinophil
count 3%.7-11 The proportion of patients with eosinophilic
asthma who could beneﬁt from anti-IL-5 therapy among a
general population of adult-onset asthmatics has, however,
remained unknown.The proportion of patients with severe asthma (SA) has been
approximated to be 5% to 10% among all patients with
asthma.12 However, there have been difﬁculties in assessing the
true prevalence due to the lack of accurate deﬁnition13 and
exclusion of signiﬁcant patient groups (smoking, aged in-
dividuals, and patients with signiﬁcant comorbidities) from most
published clinical cohorts. A European Respiratory Society/
American Thoracic Society (ERS/ATS) committee deﬁned SA as
asthma requiring treatment with high ICS dose together with
add-on medication or OCS to prevent it from becoming un-
controlled or which remains uncontrolled despite this therapy.12
This study was carried out to evaluate the proportion of
patients fulﬁlling combinations of possible clinical criteria for the
use of anti-IL-5 therapies as well as the prevalence of SA in a real-
life cohort of patients with clinically deﬁned adult-onset asthma
12 years after diagnosis. Another aim was to compare the clinical
characteristics of patients with non-SA and SA and those ful-
ﬁlling criteria for anti-IL-5 therapy.
METHODS
Study design and patients
This study is part of Seinäjoki Adult Asthma Study (SAAS).
SAAS (ClinicalTrials.gov ID NCT02733016) is a prospective,
single-center (Seinäjoki Central Hospital, Seinäjoki, Finland) 12-
year follow-up study of a cohort of patients having new-onset
asthma diagnosed at adult age (15 years). Institutional permis-
sions were obtained and the participants gave written informed
consent to the study protocol approved by the ethics committee of
Tampere University Hospital, Tampere, Finland. More than 94%
of the patients diagnosed with novel asthma in the study site were
recruited to the study.14 In 2001, the study population represented
>38% of novel diagnoses of asthma made to adults in the whole
geographical area. The protocol, inclusion and exclusion criteria,
and the background data of the SAAS study have been published
separately.14 Brieﬂy, asthma was diagnosed by a respiratory specialist
during 1999-2002 based on typical symptoms, and diagnosis was
conﬁrmed by objective lung function measurements.14 After diag-
nosis, the patients were treated and monitored by their own
physician according to the principles of Finnish Asthma Program15
and guidelines.16 The total cohort consisted of 257 patients and 203
patients returned to the 12-year follow-up visit.17 At this visit,
asthma status and control, comorbidities, and medication were
evaluated using structured questionnaires, and lung function and
inﬂammatory parameters were measured. The basic characteristics,
12-year prognosis (remission and asthma control), detailed smoking
characteristics, and comorbidities of the study cohort have been
previously published.17-19
Data were also gathered from all asthma-related visits to health
care (primary care, private health care, and hospital clinics), exac-
erbations, acute respiratory tract infections, and hospitalizations
during the whole 12-year follow-up period. Data from the 12-year
follow-up visit and the time in between the visits were used in
assessing the proportion of anti-IL-5 eligible patients and SA. To
assess adherence in these patients, the numbers of ICS-containing
inhalers/canisters and OCS bought from pharmacies in 2012-2013
were retrieved from Social Insurance Institution of Finland.
Exacerbations and medication
The number of exacerbations was self-reported employing a
structured questionnaire ﬁlled at 12-year follow-up visit or evaluated
from the patient records (previous year). Medication for asthma was
TABLE I. Characteristics of patients at 12-year follow-up as
previously reported17
Characteristic Cohort at follow-up (n [ 203)
Age (y) 58 (14)
Male gender, n (%) 85 (41.9)
BMI (kg/m2) 28.1 (24.4-31.2)
BMI <25, n (%) 59 (29.0)
BMI 25-29.99, n (%) 73 (36.0)
BMI 30, n (%) 71 (35.0)
Smokers (incl. ex), n (%) 107 (52.7)
Smoking history, pack-year 16 (7-30)
Total IgE (kU/L) 61 (24-163)
Daily ICS use, n (%) 155 (76.4)
Blood eosinophils (109/L) 0.17 (0.10-0.27)
Blood eosinophils 0.3, n (%) 35 (17.3)
Pre-BD FEV1 % 86 (76-96)
Pre-BD FEV1 <80% predicted, n (%) 61 (30.0)
Pre-BD FVC % 96 (87-106)
Pre-BD FEV1/FVC 0.73 (0.66-0.79)
Post-BD FEV1 % 90 (80-98)
Post-BD FEV1 <80% predicted, n (%) 48 (23.6)
Post-BD FVC % 99 (88-107)
Post-BD FEV1/FVC 0.75 (0.69-0.80)
DLCO (%) 92 (19)
DLCO/VA (%) 94 (17)
AQ20 score 4 (2-7)
ACT score 22 (19-24)
ACT score <20, n (%) 56 (27.6)
ACT, Asthma Control Test; AQ20, Airways Questionnaire 20; BD, bronchodilator;
BMI, body mass index; DLCO, diffusing capacity; DLCO/VA, diffusing capacity
adjusted by the alveolar volume; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid.
Shown are mean (standard deviation) or median (25th-75th percentile).
Asthma control was evaluated by GINA 2010.22
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missing, medication was evaluated from the previous asthma-related
visit to health care.
Lung function, inflammatory parameters, and other
clinical measurements
Lung function measurements were performed with a spirometer
according to international recommendations.20 Detailed informa-
tion on the lung function measurements, determination of inﬂam-
matory parameters, comorbidities, and on other clinical
measurements can be found in this article’s Online Repository at
www.jaci-inpractice.org.
Severe asthma
SA was deﬁned according to the ATS/ERS Task Force as asthma
requiring treatment with high ICS dose together with add-on
medication or OCS to prevent it from becoming uncontrolled or
which remains uncontrolled despite this therapy.12 Uncontrolled
asthma was deﬁned as one of the following at the 12-year follow-up
visit: (1) poor symptom control (Asthma Control Test [ACT] score
< 20), (2) frequent exacerbations (2 bursts of OCS in the previous
year), (3) serious exacerbations (1 hospitalization in the previous
year due to asthma), and (4) airﬂow limitation (preeforced expira-
tory volume in 1 second (FEV1) < 80% predicted).
12
Primary and secondary endpoints
The primary endpoint of this study was to assess the proportion
of patients who could beneﬁt from anti-IL-5 therapy, that is,
patients fulﬁlling the following criteria: (1) daily use of medium-to-
high ICS dose (800 mg budesonide equivalent) and LABA, (2) 2
exacerbations per previous year before the 12-year follow-up visit,
and (3) blood eosinophil level 300 cells/mL or FeNO 50 ppb at
the 12-year follow-up visit in the SAAS cohort.
The secondary endpoints were to assess the proportion of patients
with SA (fulﬁlling ERS/ATS criteria) and the proportion of patients
fulﬁlling different combinations of the clinical criteria related to
eligibility to anti-IL-5 treatment. A further aim was to see whether
anti-IL-5 eligible patients and SA overlap. A comparison of basic and
clinical characteristics and health care use of patients fulﬁlling criteria
for anti-IL-5 therapy to those fulﬁlling criteria of SA and to the
patients with non-SA was also assessed as a secondary endpoint.
Statistical analysis
Continuous data are expressed as mean  standard deviation or
median and interquartile range. A comparison between 3 groups was
performed by using 1-way analysis of variance with Tukey’s post
hoc, Kruskal-Wallis, or c2 test. Bootstrapping21 was used to estimate
95% conﬁdence interval (CI) for the primary/secondary outcome
estimate. By this method, 1000 samples with replacement were
drawn from the original dataset of the same size as the original
sample allowing us to quantify more precisely the accuracy of pri-
mary outcome estimate. Statistical analyses were performed using
SPSS software, version 23 (IBM SPSS, Armonk, NY). P value < .05
was regarded as statistically signiﬁcant.
RESULTS
Patient characteristics
The characteristics of patients at 12-year follow-up visit are
shown in Table I. Patients were mostly females, nonatopic,
overweight, and approximately half had smoking history. The
proportion of daily ICS users was 76.4%. Asthma was uncon-
trolled in 29.6% of patients. Two patients (1%) were usingcontinuous OCS for asthma indication at 12-year follow-up visit,
and 2 patients (1%) for other indication.
Patients eligible to anti-IL-5 therapy
The primary endpoint of this study was fulﬁlled by 4 of 203
(2% of patient cohort) (Figure 1, A). With blood eosinophil
cutoff set from 150 to 400 cells/mL, proportion varied between
1% and 3% (Figure 1, A). When criteria for exacerbations and
medication use were removed, 20.3% of patients fulﬁlled criteria
for blood eosinophils 300 cells/mL or FeNO 50 ppb. With
blood eosinophil cutoffs from 150 to 400, proportion varied
from 58.7% to 14.5% (Figure 1, B).
Sometimes asthma exacerbation may be confused with acute
respiratory tract infection, and consequently, antibiotics or
doubling of ICS dose is prescribed instead of OCS. Therefore,
we applied an explorative approach. In addition to the patients
who were prescribed OCS at least twice per year, the extended
deﬁnition included also patients with 2 acute visits to health
care where antibiotics or doubling of ICS dose was prescribed
during the previous year. In the cohort, 11.3% of the patients
fulﬁlled criteria for extended deﬁnition of exacerbations and used
medium or high ICS dose and LABA for their daily therapy.
When criteria for elevated eosinophils (300 cells/mL) or FeNO
(50 ppb) were added, 3% (n ¼ 6) patients remained.
FIGURE 1. Prevalence of patients fulfilling different combinations of the clinical criteria related to eligibility to anti-IL-5 therapy in the
cohort of adult-onset asthma (n ¼ 203). A, Prevalence of patients fulfilling different criteria for the level of blood eosinophils or FeNO,
exacerbations, and use of medication. B, Prevalence of patients fulfilling different criteria for the level of blood eosinophils (B-eos) or FeNO
without the need to fulfill criteria for frequent exacerbations or use of medium-to-high ICS dose for asthma. FeNO, Fraction of exhaled
nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist.
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We used the ATS/ERS Task Force12 deﬁnition of SA. Of the
patients, 14 (6.9%) were using high-intensity medication for
asthma (high ICS dose plus second controller and/or OCS for
50% of the previous year) and 12 (5.9%) still remained un-
controlled fulﬁlling criteria of SA.12 The proportion of patients
deﬁned as uncontrolled according to the ACT score <20, 2
exacerbations last year, or prebronchodilator FEV1 <80% pre-
dicted are shown in Figure 2. There was only 1 patient who
fulﬁlled criteria for both SA and anti-IL-5 eligibility due to
different criteria for ICS dose, and in further analyses, this pa-
tient was included only into the anti-IL-5 group. Three anti-IL-5eligible patients were not regarded as having SA due to ICS dose
not classiﬁed as high according to ERS/ATS criteria.
Characteristics of patients with nonsevere asthma,
severe asthma, and those eligible to anti-IL-5
therapy
Patients with non-SA, SA, and those eligible to anti-IL-5
therapy were similar in respect to gender, age of asthma onset,
and lung function parameters at diagnosis and 12-year follow-up
visit (Table II and Table E1, available in this article’s Online
Repository at www.jaci-inpractice.org). Patients with SA were
more often current smokers at diagnosis (Table E1) and had
FIGURE 2. Prevalence of severe asthma (SA) in patients with
adult-onset asthma. High-intensity medication refers to daily use
of high ICS dose together with second controller (LABA, LTRA, or
theophylline), or systemic steroid for at least 50% of the previous
year. Definition of severe asthma includes the use of high-
intensity medication and uncontrolled asthma as defined by ACT
score <20, 2 exacerbations previous year, and/or pre-
bronchodilator FEV1 <80% predicted. ACT, Asthma control test;
FEV1, forced expiratory volume in 1 second; ICS, inhaled corti-
costeroid; LABA, long-acting b2-agonist; LTRA, leukotriene
receptor antagonist.
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when compared with the 2 other groups. In addition, patients
with SA had more often systemic rheumatic disease, thyroid
disorder, or treated dyspepsia as comorbidity at 12-year follow-
up visit (Table E2, available in this article’s Online Repository
at www.jaci-inpractice.org). Differences existed in parameters
related to asthma medication, exacerbations, symptoms, and
asthma control, which was expected because these parameters
were used in the categorization of patients (Tables II and III).
FeNO and total IgE level were the highest in patients fulﬁlling
criteria to anti-IL-5 therapy and lowest in patients with SA
(Table II). Instead, blood neutrophils were highest in patients
with SA and lowest in anti-IL-5 eligible patients at 12-year
follow-up visit (Table II). To assess adherence to steroid treat-
ment the numbers of ICS-containing inhalers/canisters as well as
packages of OCS bought from pharmacies around the follow-up
visit (2012-2013) were retrieved. All anti-IL-5-eligible patients
had bought several ICS-containing inhalers annually (mean 8.2/
year) and at least 1 OCS package (mean bought total OCS dose
1688 mg prednisolone equivalent/2 years corresponding to >5
ten-day courses of 30 mg oral prednisolone daily). One patient
classiﬁed as having SA had low adherence at the follow-up visit
but better adherence in long term. All of the remaining 10 pa-
tients classiﬁed as having SA had bought (2012-2013) annually
several ICS-containing inhalers/canisters (mean 13.5/year) and 8
had bought at least 1 package of OCS. Two were on a contin-
uous OCS therapy. The mean bought total OCS dose was 1975
mg prednisolone equivalent/2 years in those 6 patients not being
on a continuous OCS therapy.
Use of health care in patients with nonsevere
asthma, severe asthma, and those eligible to anti-
IL-5 treatment
During the 12-year follow-up period, the use of health care
was different between non-SA, SA, and anti-IL-5 groups: num-
ber of all asthma-related visits to health care and number ofunplanned visits (visits due to exacerbations and respiratory tract
infections) were higher in SA and anti-IL-5 eligible patients when
compared with nonsevere patients (Figure 3). Patients with SA
also had more frequent planned visits to health care than patients
with non-SA (Figure 3, B). However, there was no statistically
signiﬁcant difference between SA and anti-IL-5 eligible patients
in the number of all planned or unplanned health care visits. In
addition, all anti-IL-5 eligible patients had 3 sick leaves in the
past 2 years before the 12-year follow-up visit, whereas the
proportion was 16.7% in patients with SA (Table III). However,
patients with SA had most hospitalizations during the whole
12-year follow-up period (Table III).
In total, anti-IL-5 eligible patients accounted for 4.7% of all
asthma-related visits to health care and 7.9% of unplanned
asthma-related visits to health care, being 2-to 4-fold higher than
expected. Patients with SA accounted for 13% to 13.9% of all
and unplanned asthma-related visits to health care being more
than double than would be expected. Interestingly, the most
drastic difference was found in hospitalizations: although anti-IL-
5 eligible patients accounted for only 2% of all hospital admis-
sions (the same as expected), patients with SA accounted for 31%
of all hospitalizations, which is 5-fold more than expected.
Estimation of confidence interval for the prevalence
of anti-IL-5 eligible patients and severe asthma
Of the total cohort of adult-onset asthma, 2% were eligible for
anti-IL-5 therapy and 5.9% were classiﬁed as having SA. By
using the bootstrapping method, the 95% CI limits for these
estimates are 0.5% to 4.1% for anti-IL-5 eligible patients and
2.9% to 9.4% for SA.
DISCUSSION
In this study, we have evaluated the prevalence of patients
eligible for anti-IL-5 therapy in a cohort of adult-onset asthma
with inclusion of all levels of asthma severity and patient groups
such as smokers and those with comorbidities. Of the total
cohort, 2% were found to fulﬁll the criteria for anti-IL-5 eligi-
bility, namely daily use of medium-to-high ICS dose and LABA,
at least 2 exacerbations during the previous year, blood eosino-
phils 300 cells/mL, and/or FeNO 50 ppb. In addition, we
evaluated the prevalence of SA as deﬁned by the ERS/ATS
criteria in this cohort, being 5.9% of all patients (Figure 4).
Furthermore, only 1 patient fulﬁlled criteria for both groups
(Figure 4). Patients with SA and those who fulﬁlled criteria for
anti-IL-5 eligibility were separated from nonsevere patients by
higher use of health care (all and unplanned asthma-related visits
to health care), showing that both of these patient groups
represent a major burden to health care. In addition, when
comparing patients with SA with anti-IL-5 eligible patients,
severe asthmatics were more often current smokers at diagnosis
and were obese, used higher ICS dose, and had higher blood
neutrophils 12 years after diagnosis.
Epidemiological studies on different asthma phenotypes are
rare. To our knowledge, this is the ﬁrst study where the preva-
lence of anti-IL-5-treatable asthma among patients with adult-
onset asthma was evaluated. The prevalence of anti-IL-5
eligibility among SA has been assessed in a Belgian SA
cohort including smoking patients and those with comorbidities
and 30% of patients with SA were found to be eligible for
anti-IL-5.23 The criteria for anti-IL-5 eligibility were similar to
TABLE II. Characteristics of patients with nonsevere asthma, severe asthma, and those eligible† to anti-IL-5 therapy at 12-year
follow-up visit
Characteristic Nonsevere Severe Eligible to anti-IL-5 P value
No. of patients 188 11 4
Female, n (%) 108 (57.4%) 7 (63.6%) 3 (75.0%) .726
Age at onset (y) 47 (37-56) 52 (41-55) 49 (40-70) .748
BMI (kg/m2) 28.4 (5.5) 32.5 (5.8)* 25.6 (5.1) .033
With smoking history, n (%) 97 (51.6 %) 8 (72.7%) 2 (50.0%) .392
Current smokers, n (%) 26 (13.8%) 4 (36.4%) 0 .086
Pack-years of smokers 16 (7-30) 18 (15-21) 31 (42) .799
Atopic, n (%) 63 (37.3%) 3 (30%) 2 (50.0%) .778
Lung function
Pre-BD FEV1 (% pred) 86 (18) 81 (19) 79 (16) .557
Post-BD FEV1 (% pred) 89 (17) 83 (19) 81 (18) .399
Post-FEV1/FVC 0.76 (0.69-0.81) 0.72 (0.68-0.74) 0.71 (0.51-0.79) .150
DLCO/VA, % predicted 96 (16) 92 (18) 87 (25) .462
Daily medication
ICS, n (%) 140 (74.5%) 11 (100%) 4 (100%) .081
LABA, n (%) 82 (43.6%) 10 (90.9%)* 4 (100%) .001
LTRA, n (%) 22 (11.7%) 5 (45.5%)* 0 .005
LAMA, n (%) 5 (2.7%) 2 (18.2%)* 1 (25%)* .003
Theophylline, n (%) 2 (1.1%) 2 (18.2%) 0 <.001
No. of add-on drugs 1 (0-1) 2 (1-2)* 1.5 (1-2) <.001
ICS dosez 786 (406) 2140 (844)* 1333 (577)** <.001
High ICS dose,x n (%) 4 (2.1%) 11 (100%)* 1 (25 %)*,** <.001
Systemic steroid, n (%) 1 (0.5%) 3 (27.3%) 0 <.001
Symptoms/quality of life
AQ20 score 4 (1-7) 8 (4-15)* 8 (3-10) .005
ACT score 22 (20-24) 16 (10-19)* 18.5 (13.3-23.8) <.001
ACT  20 144 (76.6%) 1 (9.1%)* 2 (50%) <.001
ACT 16-19 26 (13.8%) 5 (45.5%) 0
ACT < 16 18 (9.6%) 5 (45.5%) 2 (50%)
Asthma control, GINA 2010, n (%) .055
Controlled 68 (36.2%) 1 (9.1%) 0
Partially controlled 69 (36.7%) 4 (36.4%) 1 (25.0%)
Uncontrolled 51 (27.1%) 6 (54.5%) 3 (75.0%)
Inﬂammation
Blood eosinophils (109/L) 0.17 (0.10-0.27) 0.13 (0.10-0.28) 0.46 (0.12-0.71) .203
Blood eosinophils  0.3 109/L 31 (16.6%) 2 (18.2%) 2 (50.0%) .217
FeNO (ppb) 11 (5-18) 8 (6-15) 41 (13-56) .043
FeNO  50 ppb 8 (4.5%) 0 2 (50.0 %)*,** <.001
Total IgE (kU/L) 61 (25-161) 22 (9-76) 307 (67-552) .038
Blood neutrophils (109/L) 3.9 (1.4) 6.3 (2.5)* 2.5 (0.6)** <.001
ACT, Asthma Control Test; AQ20, Airways Questionnaire 20; ATS, American Thoracic Society; BD, bronchodilator; BMI, body mass index;DLCO/VA, diffusing capacity adjusted
by the alveolar volume;ERS, European Respiratory Society;FeNO, fraction of exhaled nitric oxide;FEV1, forced expiratory volume in 1 s;FVC, forced vital capacity;GINA, Global
Initiative for Asthma; ICS, inhaled corticosteroid; LAMA, long-acting muscarinic receptor antagonist; LABA, long-acting b2-agonist; LTRA, leukotriene receptor antagonist.
Shown are n (%) for categorical variables, and mean (standard deviation) or median (interquartile range) for continuous variables.
Bold indicates statistical signiﬁcance (P < .05).
*P < .05 vs nonsevere.
**P < .05 vs severe group.
†Anti-IL-5 eligible patients refer to those who fulﬁll criteria for the primary endpoint of this study (daily use of medium-to-high ICS dose and LABA, 2 exacerbations per
previous year, and blood eosinophil level  300 cells/mL or FeNO  50 ppb).
zICS dose as budesonide equivalents (mg).
xBased on ERS/ATS criteria.14
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higher ICS dose requirement (880 mg ﬂuticasone equivalent)
and with inclusion of sputum eosinophils 3%. A multicenter
study also assessed eligibility to anti-IL-5 antibodies mepolizu-
mab and reslizumab among “real-world” patients with SA andfound eligibilities of 20% and 6% for these agents, respectively.24
However, the results are difﬁcult to compare with our result due
to different patient cohorts (severe vs general) and different
criteria used for eligibility (eosinophil count 150 for mepoli-
zumab or 400 cells/mL for reslizumab vs 300 cells/mL in our
TABLE III. Characteristics of patients with nonsevere asthma, severe asthma, and those eligible† to anti-IL-5 therapy during the 12-year
follow-up period
Characteristic Nonsevere Severe Eligible to anti-IL-5 P value
No. of patients 188 11 4
Lung function decline per yearz
DFEVz (mL) 46 (36) 65 (43) 65 (31) .152
DFEV1 (% predicted) 0.5 (1.0) 1.0 (1.4) 1.2 (0.9) .183
Exacerbations
Use of oral steroid coursesx 56 (30.1%) 5 (50%) 4 (100%)* .006
No. of OCS bursts/2 y{ 1 (1-2) 3 (1-7) 5 (3-9)* .002
3 sick leaves/2 y# 3 (2.0%) 1 (16.7%) 3 (100%)††* <.001
Use of health care
Hospitalizations, n 0 (0-0) 2 (0-4)* 0.5 (0-1.75) .005
1 hospitalization, any respiratory reason (planned and unplanned) 43 (23.0%) 6 (54.5%) 2 (50.0%) .033
1 hospitalization, any respiratory reason (unplanned) 17 (9.1%) 4 (36.4%)* 1 (25.0%) .013
1 hospitalization, asthma-related (planned and unplanned) 29 (15.6%) 4 (36.4%) 1 (25.0%) .185
1 hospitalization, asthma-related (unplanned) 10 (5.4%) 1 (9.1%) 0 .774
Hospital days, any respiratory reason (planned and unplanned) 0 (0-0) 2 (0-22)* 1.5 (0-4.5) .015
Hospital days, any respiratory reason (unplanned) 0 (0-0) 0 (0-21)* 0 (0-2) .007
Hospital days, asthma-related (planned and unplanned) 0 (0-0) 0 (0-14) 0 (0-4) .134
Hospital days, asthma-related (unplanned) 0 (0-0) 0 (0-0) 0 (0-0) .746
FeNO, Fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; OCS, oral corticosteroid.
Shown are n (%) for categorical variables, and mean (standard deviation) or median (interquartile range) for continuous variables.
Bold indicates statistical signiﬁcance (P < .05).
*P < .05 vs nonsevere.
†Anti-IL-5 eligible patients refer to those who fulﬁll criteria for the primary endpoint of this study (daily use of medium-to-high ICS dose and LABA, 2 exacerbations per
previous year, and blood eosinophil level  300 cells/mL or FeNO  50 ppb).
zDecline in FEV1 from the point of maximal lung function within 2.5 y after diagnosis (and start of therapy) to the 12-year follow-up visit.
xPatients who have used oral steroid bursts at least once during the 12-year follow-up period.
{Number of oral steroid bursts in previous 2 y before 12-y follow-up visit among those who needed oral steroid bursts.
#Sick leaves related to asthma in the past 2 y before the 12-y follow-up visit.
††One patient with missing information.
FIGURE 3. A, Asthma-related visits to health care in patients with nonsevere asthma, severe asthma, and eligible for anti-IL-5 therapy. B,
Planned visits include asthma-related follow-up visits. C, Unplanned visits include visits related to exacerbations and acute respiratory
tract infections. Anti-IL-5 eligible patients refer to those who fulfill criteria for the primary endpoint of this study (daily use of medium-to-
high ICS dose and LABA, 2 exacerbations per previous year, and blood eosinophil level  300 cells/mL or FeNO  50 ppb). FeNO,
Fraction of exhaled nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist.
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study, 1 for reslizumab). In addition, criteria for FeNO were
not included in that study consistently with the Food and Drug
Administrationeapproved criteria for anti-IL-5 antibodies. ERS/
ATS criteria12 (used in our study) for high ICS dose in SA were
very strict and much higher than that deﬁned by Global Initiative
for Asthma (GINA), and as a consequence most anti-IL-5 eligible
patients were not deﬁned as severe asthmatics in our study. Only
1 patient overlap in these 2 groups is a surprising and interesting
ﬁnding and reﬂects the strict criteria for SA by ATS/ERS andconfusing current state of multiple deﬁnitions for high ICS dose.
Despite not belonging to the group of SA, all anti-IL-5-treatable
patients fulﬁlled 1 or more features of uncontrolled asthma (3
patients uncontrolled, 1 partially controlled according to GINA
2010). If patients with SA and those with anti-IL-5 eligibility are
combined, the proportion of anti-IL-5 eligible patients in this
group is 27%, similarly to the Belgian registry.
We also evaluated the prevalence of eosinophilic phenotype of
adult-onset asthma in the whole study cohort by using different
cutoff points. The proportions of eosinophilic asthma by using
FIGURE 4. Prevalence of anti-IL-5 eligible asthma, severe asthma,
and nonsevere asthma in cohort of adult-onset asthma (SAAS).
One patient overlap existed in the groups of anti-IL-5 eligibility and
severe asthma. CI, Confidence interval; SAAS, Seinäjoki Adult
Asthma Study.
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17.3% and 10.4%, respectively. Previous studies found 26.4%25
and 16%26 prevalence by using the same cutoffs, respectively,
but used selected cohorts (exclusion of patients with coexisting
chronic obstructive pulmonary disease26 or inclusion of those
with regular treatment [medium-to-high ICS dose] to asthma25).
So far, little is known about the prevalence of SA among all
asthmatics even though estimates of 5% to 10% have often been
proposed with unclear basis for the estimate. Previous pharmacy-
based studies have found the prevalence of SA from 3.6% (Dutch
study)13 to 4.6% (Israeli study).27 In the Dutch study, only
3.6% were deﬁned as having SA after excluding those with poor
adherence or an incorrect inhalation technique. In our study with
patients having asthma diagnosis clinically conﬁrmed by respi-
ratory specialist and lung function measurements, 5.9% (CI
2.9% to 9.4%) were classiﬁed as having SA according to the
deﬁnition agreed by the ATS/ERS Task Force.12 Even though
the prevalence estimates (3.6% to 4.6%) obtained from the
pharmacy-based studies13,27 are somewhat lower, they fall within
the 95% CI (2.9% to 9.4%) for SA obtained in the present
study, and suggest that pharmacy database studies may be a way
forward to obtain crude estimates of SA. Differences in the age of
asthma onset, lack of objective asthma diagnosis, exclusion of
heavy smokers, and deﬁnition of SA may affect the difference
seen between the prevalence of SA in our and the previous
studies.13,27
SA is not a single disease, but a heterogeneous group with
many subphenotypes. Age at disease onset has been found as a
differentiating factor for asthma phenotypes in many studies,
separating allergic and atopic early-onset phenotype from less
allergic adult-onset phenotypes.1,3,28,29 Adult-onset sub-
phenotypes such as eosinophilic inﬂammation-predominant,
mild-to-moderate well-controlled, obese noneosinophilic,
smoking asthma, and severe obstructive asthma have been
identiﬁed by several cluster analyses.1 Late-onset severe eosin-
ophilic asthma represents only 1 subphenotype, and in a study
of this size, a random predominance of a particular phenotype
may have affected the proportion of subjects identiﬁed as anti-
IL-5 eligible. In the Belgian SA registry,23 the prevalence of theeosinophilic phenotype (blood eosinophils 300 cells/mL) in
the SA cohort was 36%. Inﬂammation in our patients with SA
was often neutrophil predominant. This is in concordance with
previous studies in which SA has been associated with
neutrophilic airway inﬂammation.30,31 Whether neutrophilic
inﬂammation is due to different pathological mechanisms in
SA, or a response to high-dose glucocorticoid treatment in
these patients, remains unknown. Neutrophilia as well as low
number of patients with SA with elevated blood eosinophils in
our cohort may also be related to good adherence to ICS
treatment.
To our knowledge, there exist no studies with comparison
between SA and anti-IL-5 eligible patients. Severe (uncontrolled)
asthma has been associated with the increased use of health care,
obesity, and smoking in previous studies when compared with
nonsevere asthmatics,27 being consistent with our results.
Number of hospital admissions and visits to general practitioner
and asthma specialist have been reported to be higher in patients
with SA as compared with nonsevere patients in follow-up for 1
year.27 In a US study with 11-month follow-up, patients with
eosinophilic (400 cells/mL) SA (severity deﬁned solely by use of
medication) were reported to be more often hospitalized but had
no more outpatient or emergency room visits when compared
with those with normal eosinophils.32 In contrast, in our study,
anti-IL-5 eligible patients visited health care frequently, had the
high number of oral steroid courses and sick leaves, but hospi-
talizations were not increased as compared with SA. Frequency of
hospitalizations in patients with SA may be partly explained by
obesity and smoking as well as comorbidities, all being associated
with poor outcome of asthma.17,19,33
The estimate for anti-IL-5 eligible patients in this general
population of asthmatics was 2%. A major limitation of this
study is the relatively small sample size. However, by using
bootstrap analysis relatively narrow, 95% CI of 0.5% to 4.1%
for anti-IL-5 eligibility was obtained. Another limitation
affecting the generalizability of our ﬁndings is the relatively low
rate of patients with uncontrolled asthma in our cohort (29.6%)
when compared with previous studies varying from 27% to
74%.34-37 Different patient population and method for assessing
control of asthma as well as better adherence to treatment in our
study may explain the difference. On the other hand, good
adherence to treatment is essential when considering biological
drugs and can be considered as a strength when assessing the
prevalence of anti-IL-5 eligibility. Many patients with SA suffer
from multimorbidity (including reﬂux disease or sinusitis),38 and
if comorbidities are addressed properly, this can lead to resto-
ration of asthma control and obviate the need for prescribing a
biologic agent. Our anti-IL-5 eligible patients had very few
comorbidities altogether, and none of the 4 anti-IL-5 eligible
patients reported reﬂux disease. Sinusitis was not objectively
evaluated in the follow-up visit in each patient but during the
12-year time, 3 of the 4 anti-IL-5 eligible patients had had
several visits to health care because of sinus problems and were
prescribed permanent nasal steroid for long-term rhinitis.
However, we cannot exclude the possibility that sinus problems
have affected asthma development into severe form and whether
they could have been better addressed. In addition, our study
excluded childhood-onset asthmatics, also limiting the general-
izability of the ﬁndings.
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clinical indications approved or used in studies. Despite the
clinical beneﬁts of anti-IL-5 treatment, the drugs are costly, and
according to a preliminary cost-effectiveness analysis of mepoli-
zumab, it may exceed commonly used thresholds.39 The pre-
liminary cost-effectiveness analysis has been based on data
available from clinical trials. Thus, it is possible that in the future
anti-IL-5 therapy will be targeted differently. Recent studies
suggest that the characteristics of patients obtaining better beneﬁt
may include those with higher eosinophil levels40,41 and asthma
onset after 40 years.42
In summary, in an unselected cohort of adult-onset asthma,
we have shown 2% prevalence of eosinophilic steroid-resistant
exacerbation-prone asthma that could beneﬁt from the anti-IL-
5 antibody and 5.9% prevalence of SA. Only 1 patient met
criteria for both groups. Patients with SA and those eligible for
anti-IL-5 therapy differed by current smoking, obesity, and
more neutrophil-predominant disease in patients with SA.
According to our results including exceptionally long 12-year
follow-up data of health care use, both groups are a high
burden to health care, suggesting that the current treatments
are ineffective for these patients. It is important to identify
these phenotypes as early as possible because they may beneﬁt
from targeted treatment that could lead to lower long-term use
of health care.
Acknowledgment
Aino Sepponen, RN, is gratefully acknowledged for her help
through all the stages of this work.
REFERENCES
1. Ilmarinen P, Tuomisto LE, Kankaanranta H. Phenotypes, risk factors and
mechanisms of adult-onset asthma. Mediators Inﬂamm 2015;2015:514868.
2. Ilmarinen P, Tuomisto LE, Niemelä O, Tommola M, Haanpää J,
Kankaanranta H. Cluster analysis on longitudinal data of patients with adult-
onset asthma. J Allergy Clin Immunol Pract 2017;5:967-978.e3.
3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular
approaches. Nat Med 2012;18:716-25.
4. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P,
et al. Asthma exacerbations and sputum eosinophil counts: a randomised
controlled trial. Lancet 2002;360:1715-21.
5. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in
allergic asthma. Basic Clin Pharmacol Toxicol 2013;114:109-17.
6. Kankaanranta H, Moilanen E, Zhang X. Pharmacological regulation of human
eosinophil apoptosis. Curr Drug Targets Inﬂamm Allergy 2005;4:433-45.
7. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al.
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
N Engl J Med 2014;371:1189-97.
8. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-
blind, placebo-controlled trial. Lancet 2012;380:651-9.
9. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Resli-
zumab for inadequately controlled asthma with elevated blood eosinophil levels:
a randomized phase 3 study. Chest 2016;150:789-98.
10. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al.
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J
Med 2009;360:973-84.
11. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al.
Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus
placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-
ranging study. Lancet Respir Med 2014;2:879-90.
12. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Inter-
national ERS/ATS guidelines on deﬁnition, evaluation and treatment of severe
asthma. Eur Respir J 2014;43:343-73.13. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH.
The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135:
896-902.
14. Kankaanranta H, Ilmarinen P, Kankaanranta T, Tuomisto LE. Seinajoki Adult
Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of
new-onset asthma diagnosed at adult age and treated in primary and specialised
care. NPJ Prim Care Respir Med 2015;25:15042.
15. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, et al.
A 10 year asthma programme in Finland: major change for the better. Thorax
2006;61:663-70.
16. Haahtela T, Lehtimaki L, Ahonen E, Harju T, Jartti T, Kankaanranta H, et al.
Update on current care guidelines: asthma. Duodecim 2013;129:994-5.
17. Tuomisto LE, Ilmarinen P, Niemela O, Haanpaa J, Kankaanranta T,
Kankaanranta H. A 12-year prognosis of adult-onset asthma: Seinajoki Adult
Asthma Study. Respir Med 2016;117:223-9.
18. Tommola M, Ilmarinen P, Tuomisto LE, Haanpää J, Kankaanranta T,
Niemelä O, et al. The effect of smoking on lung function: a clinical study on
adult-onset asthma. Eur Respir J 2016;48:1298-306.
19. Ilmarinen P, Tuomisto LE, Niemelä O, Danielsson J, Haanpää J,
Kankaanranta T, et al. Co-morbidities and elevated IL-6 associate with negative
outcome in adult-onset asthma. Eur Respir J 2016;48:1052-62.
20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.
Standardisation of spirometry. Eur Respir J 2005;26:319-38.
21. Mantalos P, Zografos K. Interval estimation for a binomial proportion: a
bootstrap approach. J Stat Comput Simul 2008;78:1251-65.
22. Global Initiative for Asthma. From the global strategy for asthma management
and prevention. Updated 2010. Available from: http://www.ginasthma.org/.
Accessed October 27, 2014.
23. Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al.
Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma
registry (BSAR). Respir Med 2014;108:1723-32.
24. Albers FC, Müllerovr H, Gunsoy NB, Shin J-Y, Nelsen LM, Bradford ES, et al.
Biologic treatment eligibility for real-world patients with severe asthma: the
IDEAL study. J Asthma 2018;55:152-60.
25. de Groot JC, Storm H, Amelink M, de Nijs SB, Eichhorn E, Reitsma BH, et al.
Clinical proﬁle of patients with adult-onset eosinophilic asthma. ERJ Open Res
2016;2:00100-002015.
26. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al.
Blood eosinophil count and prospective annual asthma disease burden: a UK
cohort study. Lancet Respir Med 2015;3:849-58.
27. Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community:
a large electronic database analysis. Respir Med 2017;123:131-9.
28. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe
asthma phenotypes: role of age at onset and eosinophilic inﬂammation.
J Allergy Clin Immunol 2004;113:101-8.
29. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al.
Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med
2008;178:218-24.
30. Wenzel SE, Szeﬂer SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bron-
choscopic evaluation of severe asthma. Persistent inﬂammation associated
with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:
737-43.
31. Macedo P, Hew M, Torrego A, Jouneau S, Oates T, Durham A, et al. Inﬂam-
matory biomarkers in airways of patients with severe asthma compared with
non-severe asthma. Clin Exp Allergy 2009;39:1668-76.
32. Casciano J, Krishnan JA, Small MB, Buck PO, Gopalan G, Li C, et al.
Burden of asthma with elevated blood eosinophil levels. BMC Pulm Med
2016;16:100.
33. Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging co-morbidities
in adult asthma: risks, clinical associations and mechanisms. Mediators Inﬂamm
2016;2016:3690628.
34. Mintz M, Gilsenan AW, Bui CL, Ziemiecki R, Stanford RH, Lincourt W, et al.
Assessment of asthma control in primary care. Curr Med Res Opin 2009;25:
2523-31.
35. Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST. Real-world
Evaluation of Asthma Control and Treatment (REACT): ﬁndings from a
national Web-based survey. J Allergy Clin Immunol 2007;119:1454-61.
36. Lenoir M, Williamson A, Stanford RH, Stempel DA. Assessment of asthma
control in a general population of asthmatics. Curr Med Res Opin 2006;22:
17-22.
37. Carlton BG, Lucas DO, Ellis EF, Conboy-Ellis K, Shoheiber O, Stempel DA.
The status of asthma control and asthma prescribing practices in the United
J ALLERGY CLIN IMMUNOL PRACT
JANUARY 2019
174 ILMARINEN ETALStates: results of a large prospective asthma control survey of primary care
practices. J Asthma 2005;42:529-35.
38. Lang DM. Multimorbidity: the new normal. Ann Am Thorac Soc 2013;10:491-3.
39. Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH,
Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic
asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol 2017;118:
220-5.
40. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al.
Severe eosinophilic asthma treated with mepolizumab stratiﬁed by baselineeosinophil thresholds: a secondary analysis of the DREAM and MENSA
studies. Lancet Respir Med 2016;4:549-56.
41. Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P, et al. Com-
parison of anti-interleukin-5 therapies in patients with severe asthma: global and
indirect meta-analyses of randomized placebo-controlled trials. Clin Exp
Allergy 2017;47:129-38.
42. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with
inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm
Pharmacol Ther 2017;43:39-45.
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 7, NUMBER 1
ILMARINEN ETAL 174.e1ONLINE REPOSITORY
Lung function, inflammatory parameters, and other
clinical measurements
Lung function measurements were performed with a
spirometer (Vmax Encore 22, Viasys Healthcare, Palm Springs,
Calif) that was calibrated daily. Postbronchodilator measure-
ments were taken 15 minutes after inhalation of salbutamol
(400 mg). Finnish reference values were used.E1 Fraction of
exhaled nitric oxide was measured with a portable rapid-response
chemiluminescent analyzer according to American Thoracic
Society standardsE2 (ﬂow rate 50 mL/s; NIOX System, Aero-
crine, Sweden). Venous blood was collected and white blood celldifferential counts were determined. Total IgE levels were
measured by using ImmunoCAP (Thermo Scientiﬁc, Uppsala,
Sweden). Laboratory assays were performed in an accredited
laboratory (SFS-EN ISO/IEC 17025:2005 and ISO
15189:2007) of Seinäjoki Central Hospital. The deﬁnition of
comorbidities and their classiﬁcation was based on a previous
study.E3 Comorbidities were self-reported or based on self-
reported medication, and unclear cases were conﬁrmed from
patient records.E4 Patients completed Airways Questionnaire 20
(AQ20) and Asthma Control Test. AQ20 is a short and simple
well-validated questionnaire to measure and quantify distur-
bances in the airway-speciﬁc quality of life.E5 Assessment of
asthma control was performed according to the Global Initiative
for Asthma (2010) report.E6
TABLE E1. Baseline characteristics of patients with nonsevere asthma, severe asthma, and those eligible* to anti-IL-5 therapy
Characteristic Nonsevere Severe Eligible to anti-IL-5 P value
No. of patients 188 11 4
BMI 27.3 (4.9) 30.9 (6.3) 26.4 (3.2) .059
Smokers, ex þ current 93 (49.5%) 8 (72.7%) 2 (50.0%) .325
Current smokers 30 (16.0%) 5 (45.5%)† 1 (25.0%) .042
Pack years of smokers 11 (5-21) 15 (9-17) 25 (0-ND) .859
Duration of asthma symptoms before diagnosis (mo) 12 (12-36) 12 (9-36) 30 (8-102) .873
Symptoms of asthma <16 y 40 (21.6%) 4 (36.4%) 1 (25%) .520
Lung function
Pre-BD FEV1 80 (18) 84 (13) 69 (28) .375
Post-BD FEV1 86 (18) 88 (11) 81 (26) .746
Pre-BD FVC 89 (16) 91 (16) 83 (14) .742
Post-BD FVC 92 (16) 93 (12) 92 (5) .954
Pre-BD FEV1/FVC 0.74 (0.10) 0.77 (0.06) 0.65 (0.20) .150
Post-BD FEV1/FVC 0.78 (0.10) 0.78 (0.06) 0.70 (0.21) .360
FEV1 reversibility (mL) 160 (70-330) 140 (0-200) 365 (148-470) .253
FEV1 reversibility (% change from baseline) 6.1 (2.7-11.3) 4.0 (0-7.1) 20.7 (4.7-39.0) .177
DLCO/VA (% predicted) 101 (18) 97 (20) 92 (11) .540
Response to treatment (DFEV1 DG-Max0-2.5) (mL) 255 (70-590) 290 (20-540) 280 (225-1700) .689
Response to treatment (DFEV1 DG-Max0-2.5) (% predicted) 9.0 (3.0-16.9) 8 (3.0-14.6) 15.9 (7.3-45.7) .365
Daily medication
ICS in use before diagnosis 14 (7.5%) 1 (10.0%) 1 (25%) .428
ICS starting dose (all, bud eq, mg) 991 (537) 1145 (573) 900 (503) .610
Inﬂammatory parameters
Blood eosinophils 0.29 (0.15-0.42) 0.22 (0.18-0.40) 0.40 (0.08-ND) .976
Total IgE 84 (36-194) 61 (22-91) 182 (63-ND) .196
Symptoms/quality of life
AQ20 score 7 (4-9) 8 (5-13) 5 (4-11) .475
Comorbidities
Hypertension, n (%) 26 (13.8%) 3 (27.3%) 1 (25.0%) .401
Diabetes, n (%) 2 (1.1%) 1 (9.1%) 0 .097
Coronary heart disease, n (%) 10 (5.3%) 0 0 .657
COPD 13 (7.1%) 1 (9.1%) 1 (25%) .397
AQ20, Airways Questionnaire 20; BD, bronchodilator; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO/VA, diffusing capacity adjusted by the
alveolar volume; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting
b2-agonist.
Bold indicates statistical signiﬁcance (P < .05).
*Anti-IL-5 eligible patients refer to those who fulﬁll criteria for the primary endpoint of this study (daily use of medium-to-high ICS dose and LABA, 2 exacerbations per
previous year before the 12-y follow-up visit, and blood eosinophil level  300 cells/mL or FeNO  50 ppb).
†Indicates P < .05 versus nonsevere group.
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TABLE E2. Comorbidities of patients with nonsevere asthma, severe asthma, and those eligible* to anti-IL-5 therapy at 12-year follow-up
visit
Characteristic Nonsevere Severe Eligible to anti-IL-5 P value
No. of patients 188 11 4
No. of comorbidities 1 (0-2) 2 (1-3) 0.5 (0-2.5) .137
Hypertension 64 (34.0%) 4 (36.4%) 1 (25%) .918
Diabetes 27 (14.4 %) 2 (18.2%) 0 .669
Obesity 63 (33.5%) 7 (63.6%) 1 (25%) .115
Coronary heart disease 20 (10.6%) 1 (9.1%) 0 .780
Any psychiatric disease 24 (12.8%) 3 (27.3%) 0 .283
Depression 15 (8.0%) 2 (18.2%) 0 .410
Systemic rheumatic disease 4 (2.1%) 2 (18.2%) 0 .009
Thyroid disorder 12 (6.4%) 4 (36.4%) 0 .001
Painful condition 18 (9.6%) 1 (9.1%) 0 .809
Treated dyspepsia 13 (6.9%) 3 (27.3%) 0 .043
COPD (fulﬁlls criteria 10 pack-years and post-BD FEV1/FVC <0.7) 30 (16.1%) 3 (27.3%) 1 (25%) .575
Rhinitis (chronic/allergic) 126 (68.5%) 10 (90.9%) 4 (100%) .121
BD, Bronchodilator; COPD, chronic obstructive pulmonary disease; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
ICS, inhaled corticosteroid; LABA, long-acting b2-agonist.
*Anti-IL-5 eligible patients refer to those who fulﬁll criteria for the primary endpoint of this study (daily use of medium-to-high ICS dose and LABA, 2 exacerbations per
previous year before the 12-year follow-up visit, and blood eosinophil level  300 cells/mL or FeNO  50 ppb).
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